-
Je něco špatně v tomto záznamu ?
Pyrimidine-based pyrazoles as cyclin-dependent kinase 2 inhibitors: Design, synthesis, and biological evaluation
MK. Vekariya, RH. Vekariya, PS. Brahmkshatriya, NK. Shah,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
29767460
DOI
10.1111/cbdd.13334
Knihovny.cz E-zdroje
- MeSH
- cyklin-dependentní kinasa 2 antagonisté a inhibitory metabolismus MeSH
- inhibiční koncentrace 50 MeSH
- inhibitory proteinkinas chemická syntéza metabolismus MeSH
- lidé MeSH
- protein - isoformy antagonisté a inhibitory metabolismus MeSH
- pyrazoly chemie metabolismus MeSH
- pyrimidiny chemie MeSH
- racionální návrh léčiv * MeSH
- simulace molekulového dockingu MeSH
- terciární struktura proteinů MeSH
- vazebná místa MeSH
- vztahy mezi strukturou a aktivitou MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
A series of new pyrimidine-pyrazole hybrid molecules were designed as inhibitors of cyclin-dependent kinase 2. Designed compounds were docked using Glide and the compounds showing good score values and encouraging interactions with the residues were selected for synthesis. They were then evaluated using CDK2-CyclinA2 enzyme inhibition by a luminescent ADP detection assay. We show that of the 26 compounds synthesized and evaluated, at least 5 compounds were found to be highly potent (IC50 < 20 nm); which can be further optimized to have selectivity over other kinase isoforms.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19035242
- 003
- CZ-PrNML
- 005
- 20191014102311.0
- 007
- ta
- 008
- 191007s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/cbdd.13334 $2 doi
- 035 __
- $a (PubMed)29767460
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Vekariya, Mayur K $u Department of Chemistry, Gujarat University, Ahmedabad, India.
- 245 10
- $a Pyrimidine-based pyrazoles as cyclin-dependent kinase 2 inhibitors: Design, synthesis, and biological evaluation / $c MK. Vekariya, RH. Vekariya, PS. Brahmkshatriya, NK. Shah,
- 520 9_
- $a A series of new pyrimidine-pyrazole hybrid molecules were designed as inhibitors of cyclin-dependent kinase 2. Designed compounds were docked using Glide and the compounds showing good score values and encouraging interactions with the residues were selected for synthesis. They were then evaluated using CDK2-CyclinA2 enzyme inhibition by a luminescent ADP detection assay. We show that of the 26 compounds synthesized and evaluated, at least 5 compounds were found to be highly potent (IC50 < 20 nm); which can be further optimized to have selectivity over other kinase isoforms.
- 650 _2
- $a vazebná místa $7 D001665
- 650 _2
- $a cyklin-dependentní kinasa 2 $x antagonisté a inhibitory $x metabolismus $7 D051357
- 650 12
- $a racionální návrh léčiv $7 D015195
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a inhibiční koncentrace 50 $7 D020128
- 650 _2
- $a simulace molekulového dockingu $7 D062105
- 650 _2
- $a protein - isoformy $x antagonisté a inhibitory $x metabolismus $7 D020033
- 650 _2
- $a inhibitory proteinkinas $x chemická syntéza $x metabolismus $7 D047428
- 650 _2
- $a terciární struktura proteinů $7 D017434
- 650 _2
- $a pyrazoly $x chemie $x metabolismus $7 D011720
- 650 _2
- $a pyrimidiny $x chemie $7 D011743
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Vekariya, Rajesh H $u Department of Chemistry, Gujarat University, Ahmedabad, India.
- 700 1_
- $a Brahmkshatriya, Pathik S $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Prague 6, Czech Republic.
- 700 1_
- $a Shah, Nisha K $u Department of Chemistry, Gujarat University, Ahmedabad, India.
- 773 0_
- $w MED00173265 $t Chemical biology & drug design $x 1747-0285 $g Roč. 92, č. 3 (2018), s. 1683-1691
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29767460 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20191007 $b ABA008
- 991 __
- $a 20191014102735 $b ABA008
- 999 __
- $a ok $b bmc $g 1451902 $s 1073792
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 92 $c 3 $d 1683-1691 $e 20180619 $i 1747-0285 $m Chemical biology & drug design $n Chem Biol Drug Des $x MED00173265
- LZP __
- $a Pubmed-20191007